These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9474247)

  • 1. Immunological characteristics of the effector cells induced by a combination therapy with cyclophosphamide and allogeneic lymphocytes.
    Sato S; Kimura S; Nakamura T; Akuzawa Y; Kodama K; Furukawa K; Kurashige S
    Cancer Invest; 1998; 16(1):18-25. PubMed ID: 9474247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerance induction of alloreactivity by portal venous inoculation with allogeneic cells followed by the injection of cyclophosphamide. I. Specific suppression of alloreactive cytotoxic and delayed-type hypersensitivity responses as well as allograft rejection.
    Qian JH; Kokudo S; Sato S; Hamaoka T; Fujiwara H
    Transplantation; 1987 Apr; 43(4):538-43. PubMed ID: 3495052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor-sensitized T lymphocytes: potential mechanisms of action.
    Evans R
    Int J Cancer; 1984 Mar; 33(3):381-8. PubMed ID: 6607893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.
    Kedar E; Rutkowski Y; Leshem B
    Cancer Immunol Immunother; 1992; 35(1):63-8. PubMed ID: 1611625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
    Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
    Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance induction of alloreactivity by portal venous inoculation with allogeneic cells followed by the injection of cyclophosphamide. II. Cellular and molecular mechanisms underlying tolerance.
    Kokudo S; Sato S; Qian JH; Wada K; Ikegami R; Hamaoka T; Fujiwara H
    Microbiol Immunol; 1988; 32(3):283-92. PubMed ID: 3393097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy by using cyclophosphamide and tumor-sensitized lymphocytes: a possible mechanism of action.
    Evans R
    J Immunol; 1983 Jun; 130(6):2511-3. PubMed ID: 6133894
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of cyclophosphamide on in vitro correlates of tumor immunity.
    Steele G; Sjögren HO; Ankerst J
    Int J Cancer; 1974 Dec; 14(6):743-52. PubMed ID: 4377004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
    Mayumi H; Good RA
    J Exp Med; 1989 Jan; 169(1):213-38. PubMed ID: 2642528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retardation of postsurgical metastases with the use of extracted tumor-specific transplantation antigens and cyclophosphamide.
    Nomi S; Pellis NR; Kahan BD
    J Natl Cancer Inst; 1984 Oct; 73(4):943-50. PubMed ID: 6237215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.
    Peppoloni S; Mathieson BJ; Herberman RB; Overton RW; Gorelik E
    Cancer Immunol Immunother; 1987; 24(1):49-56. PubMed ID: 2949833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma.
    Guo QY; Yuan M; Peng J; Cui XM; Song G; Sui X; Lu SB
    J Exp Clin Cancer Res; 2011 Feb; 30(1):24. PubMed ID: 21352555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system.
    Nishimura Y; Eto M; Maeda T; Hiromatsu K; Nomoto K; Kong YY; Nomoto K
    Immunobiology; 1995 Aug; 193(5):420-38. PubMed ID: 8522358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclophosphamide on tumor cell sensitivity to the action of immunological effectors.
    Culo F; Marić M; Morović-Vergles J
    In Vivo; 1995; 9(5):439-46. PubMed ID: 8900921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Place AT; Artwohl JE; Valli VE
    Cancer Immunol Immunother; 2006 Apr; 55(4):459-68. PubMed ID: 15965646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.